Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We are excited to announce that Sandbox Bioscience, an ambitious biotech start-up founded by a team of virology experts from the Oxford ecosystem, has joined the BioEscalator.

Redefining Gene Therapy Delivery

With decades of technical and commercial experience in gene therapy delivery systems, and platform development; Sandbox Bio is dedicated to identifying and engineering next-gen viral delivery vectors for Gene Therapy. Their cutting-edge platform will offer scalability, target specificity, and enhanced safety compared to existing market solutions.

 

By leveraging advanced virological insights and innovative platform technologies, Sandbox Bioscience aims to redefine the standard for gene delivery, making Gene Therapies more precise, accessible, and safer for a broad range of clinical applications.

 

Harnessing the power of community

Joining the BioEscalator means that Sandbox Bioscience is now part of a vibrant community filled with early-stage start-ups focused on transforming the life sciences landscape. The team is excited to integrate into this innovative group and exchange knowledge and experiences with fellow innovators.

 

In addition to connecting with brilliant minds at the BioEscalator, being situated in Oxford's hub of world-class researchers, clinicians, and industry leaders presents Sandbox Bioscience with collaboration opportunities, access to academic insights, and potential partnerships.

 

 

 “For us at Sandbox Bio, a lab bench at the BioEscalator gives us access to cutting edge equipment, expert networks, and commercialisation support. Allowing us to rapidly develop our Gene Therapy delivery platforms without any costly delays for equipment procurement and lab setup.” George Bouverat, CEO, and Founder, Sandbox Bioscience Ltd.

 

Fast-tracked innovation

Access to the BioEscalator’s state-of-the-art shared laboratory facilities will allow Sandbox to commence lab work quickly and concentrate on developing its technology, without the weighty expense of purchasing and maintaining high-spec equipment.

 

Furthermore, Sandbox will receive robust support from the BioEscalator team, including regular business-building events and connections within the industry and with potential investors.

 

We look forward to sharing updates and news from Sandbox Bioscience Ltd. and other developments at the BioEscalator.